Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction

Canadian Journal of Physiology and Pharmacology

Volumn 75, Issue 2, 1997, Pages 83-90

  Yao, J ^a   Battell, M L ^a   McNeill, J H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diabetes induction; Streptozotocin; Toxicity; Vanadium

Indexed keywords

VANADIUM; VANADIUM DERIVATIVE; VANADYL SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STRAIN DIFFERENCE; STREPTOZOCIN DIABETES;

EID: 0030958698     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y97-003     Document Type: Article

References (39)

1. Battell, M.L., Yuen, V.G., and McNeill, J.H. 1992. Treatment of BB rats with vanadyl sulphate. Pharmacol. Commun. 1: 291-301.
2. Bernier, M., Laird, D.M., and Lane, M.D. 1988. Effect of vanadate on the cellular accumulation of pp15, an apparent product of insulin receptor kinase action. J. Biol. Chem. 263: 13 626-13 634.
3. Bhanot, S., and McNeill, J.H. 1994. Vanadyl sulfate lowers plasma insulin and blood pressure in spontaneously hypertensive rats. Hypertension (Dallas), 24: 625-632.
4. Bhanot, S., McNeill, J.H., and Bryer-Ash, M. 1994. Vanadyl sulphate prevents fructose induced hyperinsulinemia and hypertension in rats. Hypertension (Dallas), 23: 308-312.
5. Brichard, S.M., Pottier, A.M., and Henquin, J.C. 1989. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats. Endocrinology (Baltimore), 125: 2510-2516.
6. Brichard, S.M., Assimacopoulos-Jeannet, F., and Jeanrenaud, B. 1992. Vanadate treatment markedly increases glucose utilization in muscle of insulin-resistant fa/fa rats without modifying glucose transporter expression. Endocrinology (Baltimore), 131: 311-317.
7. Cam, M.C., Cros, G.H., Serrano, J.J., Lazaro, R., and McNeill, J.H. 1993. Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats. Diabetologia, 36: 218-224.
8. Cam, M.C., Faun, J., and McNeill, J.H. 1995. Concentration-dependent glucose-lowering effects of oral vanadyl are maintained following treatment withdrawal in streptozotocin-diabetic rats. Metabolism, 44: 332-339.
9. Clark, A.S., Fagan, J.M., and Mitch, W.E. 1985. Selectivity of the insulin-like actions of vanadyl on glucose and protein metabolism in skeletal muscle. Biochem. J. 232: 272-276.
10. Cohen, N., Halberstam, M., Shlimovich, P., Chang, C.J., Shamoon, H., and Rossetti, L. 1995. Oral vanadyl sulphate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 95: 2501-2509.
11. Dai, S., and McNeill, J.H. 1994. One-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate did not alter blood pressure or haematological indices. Pharmacol. Toxicol. 74: 110-115.
12. Dai, S., Thompson, K.H., and McNeill, J.H. 1994a. One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulphate. Pharmacol. Toxicol. 74: 101-109.
13. Dai, S., Thompson, K.H., Vera, E., and McNeill, J.H. 1994b. Toxicity studies on one-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate. Pharmacol. Toxicol. 75: 265-273.
14. Domingo, J.L., Llobet, J.M., Gómez, M., Corbella, J., and Keen, C.L. 1990. Effects of oral vanadium administration in streptozotocin-diabetic rats. In Metal ions in biology and medicine. Edited by Ph. Collery, L.A. Poirier, M. Manfait, and J.C. Etienne. John Libbey Eurotext, Paris. pp. 312-314.
15. Domingo, J.L., Gomez, M., Llobet, J.M., Corbella, J., and Keen, C.L. 1991a. Improvement of glucose homeostasis by oral vanadyl or vanadate treatment in diabetic rats is accompanied by negative side effects. Pharmacol. Toxicol. 68: 249-253.
16. Domingo, J.L., Ortega, A., Llobet, J.M., and Keen, C.L. 1991b. No improvement of glucose homeostasis in diabetic rats by vanadate treatment when given by gavage. Trace Elem. Med. 8: 181-186.
17. Domingo, J.L., Gomez, M., Llobet, J.M., Corbella, J., and Keen, C.L. 1991c. Oral vanadium administration to streptozotocin-diabetic rats has marked negative side-effects which are independent of the form of vanadium used. Toxicology, 66: 279-287.
18. Domingo, J.L., Sanchez, D.J., Gomez, M., Llobet, J.M., and Corbella, J. 1992. Administration of vanadyl sulphate by gavage does not normalize blood glucose levels in streptozotocin-induced diabetic rats. Res. Commun. Chem. Pathol. Pharmacol. 75: 369-372.
19. +)-ATPase inhibitor. J. Biol. Chem. 255: 5306-5312.
20. Duckworth, W.C., Solomon, S.S., Liepnieks, J., Hamel, F.G., Hand, S., and Peavy, D.E. 1988. Insulin-like effects of vanadate in isolated rat adipocytes. Endocrinology (Baltimore), 122: 2285-2289.
21. Goldfine, A.B., Simonson, D.C., Folli, F., Parti, M.E., and Kahn, C.R. 1995. Metabolic effects of sodium metavanadate in humans with insulin-dependent and non-insulin-dependent diabetes mellitus in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 80: 3311-3320.
22. Green, A. 1986. The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. Biochem. J. 238: 663-669.
23. Halberstam, M., Cohen, N., Shlimovich, P., Rossetti, L., and Shamoon, H. 1996. Oral vanadyl sulphate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes, 45: 659-666.
24. Hei, Y.-j., Chen, X., Pelech, S.L., Diamond, J., and McNeill, J.H. 1995. Skeletal muscle mitogen-activated protein kinases and ribosomal S6 kinases suppression in chronic diabetic rats and reversal by vanadium. Diabetes, 44: 1147-1155.
25. Heyliger, C.E., Tahiliani, A.G., and McNeill, J.H. 1985. Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. Science (Washington, D.C.), 227: 1474-1477.
26. Llobet, J.M., and Domingo, J.L. 1984. Acute toxicity of vanadium compounds in rats and mice. Toxicol. Lett. 23: 227-231.
27. McNeill, J.H., Yuen, V.G., Hoveyda, H.R., and Orvig, C. 1992. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. J. Med. Chem. 35: 1489-1491.
28. Meyerovitch, J., Farfel, Z., Sack, J., and Shechter, Y. 1987. Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. J. Biol. Chem. 262: 6658-6662.
29. Mongold, J.J., Cros, G.H., Vian, L., Tep, A., Ramanadham, S., Siou, G., Diaz, J., and McNeill, J.H. 1990. Toxicological aspects of vanadyl sulphate treatment of diabetic rats. Pharmacol. Toxicol. 67: 192-198.
30. Pederson, R.A., Ramanadham, S., Buchan, A.M.J., and McNeill, J.H. 1989. Long-term effects of vanadyl treatment on streptozotocin-induced diabetes in rats. Diabetes, 38: 1390-1395.
31. Ramanadham, S., Mongold, J.J., Brownsey, R.W., Cros, G.H., and McNeill, J.H. 1989. Oral vanadyl sulphate in treatment of diabetes in rats. Am. J. Physiol. 257: H904-H911.
32. Shechter, Y., and Karlish, S.J.D. 1980. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature (London), 284: 556-558.
33. Shechter, Y., and Ron, A. 1986. Effects of depletion of phosphate and bicarbonate ions on insulin action in rat adipocytes. J. Biol. Chem. 261: 14 945-14 950.
34. Shisheva, A., and Shechter, Y. 1993. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J. Biol. Chem. 268: 6463-6469.
35. Strout, H.V., Vicario, P.P., Saperstein, R., and Slater, E.E. 1989. The insulin like effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm in vivo. Endocrinology (Baltimore), 124: 1918-1924.
36. Swarup, G., Cohen, S., and Garber, D.L. 1982. Inhibition of membrane phosphotyrosyl-protein phosphatase activity by vanadate. Biochem. Biophys. Res. Commun. 107: 1104-1109.
37. Yuen, V.G., Orvig, C., and McNeill, J.H. 1993. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). Can. J. Physiol. Pharmacol. 71: 263-269.
38. Yuen, V.G., Orvig, C., and McNeill, J.H. 1995. Comparison of the glucose-lowering properties of vanadyl sulphate and bis(maltolato)oxovanadium(IV) following acute and chronic administration. Can. J. Physiol. Pharmacol. 73: 55-64.
39. Yuen, V.G., Pederson, R.A., Dai, S., Orvig, C., and McNeill, J.H. 1996. Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can. J. Physiol. Pharmacol. 74: 1001-1009.